Skip to content

Released Aug 9, 2013, after the close

10-Q filed Aug 9, 2013, 40 days after period end · 0001390478-13-000010

Q2 2013 · 10-Q
Revenue$3.38M±0.0% vs Q2 2012+23.0% vs Q1 2013
Net Income$5.39MN/M vs Q2 2012N/M vs Q1 2013
EPS Diluted-$0.11N/M vs Q2 2012N/M vs Q1 2013
Gross Profit$2,914,000±0.0%
Operating Income-$7,986,000—
Operating Cash Flowderived-$7,123,000N/M
Margins · derived
Gross margin86.2%±0.0 pt vs Q2 2012
Operating margin-236.1%
Net margin159.3%+622.4 pt vs Q2 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2013Q2 2012Q2 2011Q2 2010
Revenue$3.38M$3.38M——
Net Income$5.39M-$15.66M-$3.75M-$2.14M
EPS Diluted-$0.11-$0.03-$0.10-$0.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR